Adult

Atovaquone

General Information

Antiprotozoal agent

Restricted formulary antimicrobial: For details see OUH netFormulary

Atovaquone is only available on the OUHFT formulary as a liquid preparation.

For all information regarding interactions, contraception, pregnancy and breastfeeding and additional information, see BNF and Summary of Product Characteristics (SPC).

Standard Dose

  Oral dose
PJP pneumonia prophylaxis and treatment 750mg BD

Renal and hepatic impairment

Renal impairment

  • No dose adjustment required
  • In patients with an eGFR less than 10 ml/min/1.73m2 use with caution and monitor for side effects. 

 

Hepatic impairment

  • No dose adjustment required
  • Use with caution in significant hepatic impairment and monitor for side effects. 

References

  1. Glenmark Pharmaceuticals Europe Ltd. Atovaquone Glenmark 750 mg/5 ml oral suspension summary of product characteristics. Electronic medicines compendium. Last revision of the text 28/8/24. Accessed via www.medicines.org.uk Accessed 20/2/26.
  2. British National Formulary. Atovaquone. BNF online accessed via www.medicinescomplete.com  Accessed 20/2/26.
  3. The Renal Drug Database. Atovaquone. Last updated 11/9/23. Accessed via https://renaldrugdatabase.com Accessed 20/2/26.

Editorial Information

Last reviewed: 13 Mar 2026

Next review date: 13 Mar 2029

Author(s): AMST.